FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
